Connect with us

Health and Wellness

Considering Taking Wegova to Lose Weight? Here Are the Risks and Benefits – and How It Differs from Ozempic

Published

on

Slimming medicine Vegi is now available in Australia.

Wegovy is run as a once-weekly injection and is approved specifically for weight management. It is meant to be used together with a reduced energy food plan and increased physical activity.

So how does Wegovy work, and how much weight are you able to expect to lose while taking it? And what are the potential risks—and costs—for individuals who use it?

Let’s have a look at what science says.

What is Wegovy?

Wegovy is the brand name for the drug semaglutide. Semaglutide is a glucagon-like peptide-1 receptor agonist (GLP-1RA). This means it makes your body’s own hormone glucagon-like peptide-1, or GLP-1 for brief, work higher.

Normally, if you eat, your body releases the hormone GLP-1, which helps signal your brain that you just’re full. Semaglutides enhance this effect, leading to feelings of fullness even if you haven’t eaten anything.

Another role of GLP-1 is to stimulate the body to produce more insulin, a hormone that helps lower blood glucose (sugar) levels. That is why semaglutides are utilized in just a few years in the treatment of type 2 diabetes.

Wegovy is self-administered to the patient once per week.
S. Becker/Shutterstock

How is Wegovy different from Ozempic?

Like Wegovy, Ozempic is a semaglutide. The way Wegovy and Ozempic work in the body is actually the same. They are manufactured by the same pharmaceutical company, Novo Nordisk.

There are, nevertheless, two differences:

1) They are approved for 2 different (but related) reasons.

In Australia (and the United States) Ozempic is approved to be used to improve blood glucose levels in adults with type 2 diabetes. By effectively managing blood glucose levels, the medicine goals to reduce the risk of great complications comparable to heart disease.

Wegovy is approved to be used together with food plan and exercise for individuals who have a body mass index (BMI) of 30 or more, or 27 or more but produce other health conditions comparable to hypertension.

Wegovy can be utilized in people aged 12 and older. Like Ozempic, Wegovy is designed to reduce the risk of future health complications, including heart disease.

2) Both are injectable but are available in different concentrations.

Ozempic is on the market in disposable pens with pre-filled doses of 0.25 mg, 0.5 mg, 1 mg, or 2 mg per injection. The dose could be slowly increased to a maximum of two mg per week if needed.

Wegovy is on the market in pre-filled disposable pens with doses of 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, or 2.4 mg. Treatment is initiated at a dose of 0.25 mg once per week for 4 weeks, after which the dose is steadily increased to a maintenance dose of two.4 mg per week.

While it’s unknown what impact the introduction of Wegovy can have on the availability of Ozempic, Ozempic continues to be available It is predicted that there might be few of them until the end of 2024.

Is Wegovy effective for weight reduction?

Considering that Wegovy is a semaglutide, there’s very strong evidence can assist people reduce weight and keep it off.

Recent test found that over 4 years, participants taking Wevovy as directed experienced a mean weight reduction of 10.2% of their body weight and a discount in waist circumference of seven.7 cm.

Analyses showed that individuals who stopped taking the drug lost about two-thirds of their weight. recovered.

A man leans on the railing of a bridge
Wegovy can assist people reduce weight and keep it off – while taking the medication.
Mladen Mitrinovic/Shutterstock

What are the unwanted side effects of Wegova?

Most common unwanted side effects there’s nausea and vomiting.

However, other serious unwanted side effects are also possible due to the drug’s effects on the entire body. Thyroid tumors and cancer have been identified as risks in animal studies, but are rare in humans. scientific literature.

In the four-year-old Wegovy test16.6% of participants who received Wegovy (1,461 people) experienced an adversarial event that led to everlasting discontinuation of the drug. This was higher than 8.2% of participants (718 people) who received placebo (no energetic ingredient).

Side effects included gastrointestinal upset (including nausea and vomiting), which occurred in 10% of individuals taking Wegovy compared with 2% of individuals taking placebo.

Gallbladder dysfunction occurred in 2.8% of individuals taking Wegovy and 2.3% of individuals taking placebo.

Recently, there have been concerns about suicidal thoughts and behaviors, global evaluation greater than 36 million adversarial event reports related to the use of semaglutide (Ozempic or Wegovy) since 2000 were reviewed.

There were 107 reports of suicidal thoughts and self-harm amongst people taking semaglutide, including, unfortunately, six actual deaths. When people stopped taking the drug, 62.5% said the thoughts stopped. We do not know if the dose, weight reduction, previous mental health conditions or use of antidepressants played a job.

There are also growing concerns about the negative impact of semaglutide on our social and emotional relationships with food. Thematic AND scientific evidence suggests that individuals taking semaglutide significantly reduce their every day food intake (as expected), skipping meals and avoiding social gatherings – which isn’t very nice for people and their family members.

How can I access Wegovy?

Wegovy could be purchased at a pharmacy with a prescription from a health care provider.

But there’s a high price. Wegovy is currently not subsidized through the Pharmaceutical Benefits Scheme, leaving patients to bear the cost. The current cost is estimated at around 460 Australian dollars monthly dose.

If you’re considering Wegovy, arrange Consult your doctor for individual advice.

This article was originally published on : theconversation.com
Continue Reading
Advertisement
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Health and Wellness

Jury awarded $310 million to parents of teenager who died after falling on a ride at Florida amusement park – Essence

Published

on

By

Sun Sentinel/Getty Images

The family of Tire Sampson, the 14-yr-old who tragically died on an amusement park ride in Orlando, Florida, in 2022, has been awarded $310 million in a civil lawsuit.

Tire, who was visiting ICON Park along with his family on March 24, 2022, fell from the FreeFall drop tower. Although he was taken to a nearby hospital, he didn’t survive his injuries.

Now, greater than two years later, a jury has held the vehicle manufacturer, Austria-based Funtime Handels, responsible for the accident and awarded the Tire family $310 million. According to reports from local news stations WFTV AND KSDKthe jury reached its verdict after about an hour of deliberation.

Tyre’s parents will each receive $155 million, according to attorney spokesman Michael Haggard.

Attorneys Ben Crump and Natalie Jackson, who represented Tyre’s family, shared their thoughts on this landmark decision via X (formerly Twitter). “This ruling is a step forward in holding corporations accountable for the safety of their products,” they said in a statement.

Lawyers stressed that Tyre’s death was attributable to “gross negligence and a failure to put safety before profits.” They added that the ride’s manufacturer had “neglected its duty to protect passengers” and that the substantial award ensured it could “face the consequences of its decisions.”

Crump and Jackson said they hope the result will encourage change throughout the theme park industry. “We hope this will spur the entire industry to enforce more stringent safety measures,” they said. “Tire heritage will provide a safer future for drivers around the world.”

An investigation previously found that Tyre’s harness was locked through the descent, but he dislodged from his seat through the 430-foot fall when the magnets engaged. Tire’s death was ruled the result of “multiple injuries and trauma.”

ICON Park said at the time that it could “fully cooperate” with the authorities.

This article was originally published on : www.essence.com
Continue Reading

Health and Wellness

Tireless HIV/AIDS advocate A. Cornelius Baker dies

Published

on

By

HIV/AIDS Advocate, A. Cornelius Baker


A. Cornelius Baker, a tireless advocate of HIV and AIDS testing, research and vaccination, died Nov. 8 at his home in Washington, D.C., of hypertensive, atherosclerotic heart problems, in response to his partner, Gregory Nevins.

As previously reported, Baker was an early supporter for people living with HIV and AIDS within the Nineteen Eighties, when misinformation and fear-mongering in regards to the disease were rampant.

According to Douglas M. Brooks, director of the Office of National AIDS Policy under President Obama, it was Baker’s Christian faith that guided him toward compassion for others.

“He was very kind, very warm and inclusive – his circles, both professional and personal, were the most diverse I have ever seen, and he was guided by his Christian values,” Brooks told the outlet. “His ferocity was on display when people were marginalized, rejected or forgotten.”

In 1995, when he was executive director of the National AIDS Association, Baker pushed for June 27 to be designated National HIV Testing Day.

In 2012, he later wrote on the web site of the Global Health Advisor for which he was a technical advisor that: “These efforts were intended to help reduce the stigma associated with HIV testing and normalize it as part of regular screening.”

https://twitter.com/NBJContheMove/status/1856725113967632663?s=19

Baker also feared that men like himself, black gay men, and other men from marginalized communities were disproportionately affected by HIV and AIDS.

Baker pressured the Clinton administration to incorporate black and Latino people in clinical drug trials, and in 1994 he pointedly told the Clinton administration that he was bored with hearing guarantees but seeing no motion.

According to Lambda Legal CEO Kevin Jennings, yes that daring attitude that defines Baker’s legacy in the world of ​​HIV/AIDS promotion.

“Cornelius was a legendary leader in the fight for equality for LGBTQ+ people and all people living with HIV,” Jennings said in a press release. “In the more than twenty years that I knew him, I was continually impressed not only by how effective he was as a leader, but also by how he managed to strike the balance between being fierce and kind at the same time. His loss is devastating.”

Jennings continued: “Cornelius’ leadership can’t be overstated. For many years, he was one in all the nation’s leading HIV/AIDS warriors, working locally, nationally and internationally. No matter where he went, he proudly supported the HIV/AIDS community from the Nineteen Eighties until his death, serving in various positions including the Department of Health and Human Services, the National Association of Persons with Disabilities AIDS, and the Whitman-Walker Clinic . Jennings explained.

Jennings concluded: “His career also included several honors, including being the first recipient of the American Foundation for AIDS Research Foundation’s organization-building Courage Award. Our communities have lost a pillar in Cornelius, and as we mourn his death, we will be forever grateful for his decades of service to the community.”

Kaye Hayes, deputy assistant secretary for communicable diseases and director of the Office of Infectious Diseases and HIV/AIDS Policy, in her comment about his legacy, she called Baker “the North Star.”.

“It is difficult to overstate the impact his loss had on public health, the HIV/AIDS community or the place he held in my heart personally,” Hayes told Hiv.gov. “He was pushing us, charging us, pulling us, pushing us. With his unwavering commitment to the HIV movement, he represented the north star, constructing coalitions across sectors and dealing with leaders across the political spectrum to deal with health disparities and advocate for access to HIV treatment and look after all. He said, “The work isn’t done, the charge is still there, move on – you know what you have to do.” It’s in my ear and in my heart in the case of this job.

Hayes added: “His death is a significant loss to the public health community and to the many others who benefited from Cornelius’ vigilance. His legacy will continue to inspire and motivate us all.”

Baker is survived by his mother, Shirley Baker; his partner Nevins, who can be senior counsel at Lambda Legal; his sisters Chandrika Baker, Nadine Wallace and Yavodka Bishop; in addition to his two brothers, Kareem and Roosevelt Dowdell; along with the larger HIV/AIDS advocacy community.


This article was originally published on : www.blackenterprise.com
Continue Reading

Health and Wellness

Bovaer is added to cow feed to reduce methane emissions. Does it pass into milk and meat? And is it harmful to humans?

Published

on

By

There are growing concerns in regards to the use of feed supplements, Bowar 10to reduce methane production in cows.

Bovaer 10 consists of silicon dioxide (mainly sand), propylene glycol (food stabilizer approved by Food Safety Australia New Zealand) and lively substance 3-nitrooxypropanol (3-NOP).

There has been an enormous amount of misinformation in regards to the safety of 3-NOP, with some milk from herds fed this additive being labeled “Frankenmilk”. Others feared it could get to humans through beef.

The most significant thing is that 3-NOP is secure. Let’s clear up some major misconceptions.

Why do we want to limit methane production?

In our attempts to limit global warming, we’ve placed the best emphasis on CO₂ because the major man-made greenhouse gas. But methane is also a greenhouse gas, and although we produce less of it, it is: a much stronger greenhouse gas than CO₂.

Agriculture is the largest a man-made source of methane. As cattle herds expand to meet our growing demand for meat and milk, reducing methane production from cows is a vital way to reduce greenhouse gas emissions.

There are several ways to do that. Stopping bacteria within the stomachs of cows that produce methane one approach is to produce methane.

The methane produced by cows and sheep doesn’t come from the animals themselves, but from the microbes living of their digestive systems. 3-NO stop the enzymes that perform the last step of methane synthesis in these microorganisms.

3-NOP is not the one compound tested as a feed additive. Australian product based on seaweed, Rumin8for instance, it is also in development. Saponins, soap-like chemicals present in plants, and essential oils as well has been examined.

However, 3-NOP is currently one of the popular effective treatments.

Nitrooxypropanol structure: red balls are oxygen, gray carbon, blue nitrogen and white hydrogen.
PubChem

But is not it poison?

There are concerns on social media that Bovaer is “poisoning our food.”

But, as we are saying in toxicology, it’s the dose that makes the poison. For example, arsenic is deadly 2–20 milligrams per kilogram of body weight.

In contrast, 3-NOP was not lethal on the doses utilized in safety studies, up to 600 mg 3-NOP per kg body weight. At a dose of 100 mg per kg body weight in rats, it didn’t cause any adversarial effects.

What about reproductive issues?

The effect of 3-NOP on the reproductive organs has generated numerous commentary.

Studies in rats and cows showed that doses of 300–500 mg per kg body weight caused: contraction of the ovaries and testicles.

In comparison, to achieve the identical exposure in humans, a 70 kg human would want to eat 21–35 grams (about 2 tablespoons) of pure 3-NOP every day for a lot of weeks to see this effect.

No human will likely be exposed to this amount because 3-NOP doesn’t pass into milk – is fully metabolized within the cow’s intestines.

No cow will likely be exposed to these levels either.

The cow licks itself
Cows will not be exposed to levels tested on animals in laboratory studies.
Ground photo/Shutterstock

What about cancer?

3-NOP is not genotoxic or mutagenicwhich implies it cannot damage DNA. Thus, the results of 3-NOP are dose-limited, meaning that small doses will not be harmful, while very high doses are (unlike radiation where there is no secure dose).

Scientists found that at a dose of 300 mg per kilogram of body weight benign tumors of the small intestine of female ratsbut not male rats, after 2 years of every day consumption. At a dose of 100 mg 3-NOP per kg body weight, no tumors were observed.

Cows eat lower than 2 grams of Bovaer 10 per day (of which only 10% or 0.2 grams is 3-NOP). This is about 1,000 times lower than the appropriate every day intake 1 mg 3-NOP per kg body weight per day for a cow weighing 450 kg.

This level of consumption will likely be not the result in cancer or any of them other adversarial effects.

So how much are people exposed to?

Milk and meat consumers will likely be exposed to zero 3-NOP. 3-NOP doesn’t penetrate milk and meat: is completely metabolized within the cow’s intestines.

Farmers could also be exposed to small amounts of the feed additive, and industrial employees producing 3-NOP will potentially be exposed to larger amounts. Farmers and industrial employees already wear personal protective equipment to reduce exposure to other agricultural chemicals – and it is advisable to do that with Bovear 10 as well.

Milk
3-NOP doesn’t penetrate milk and meat.
Shutterstock

How widely has it been tested?

3-NOP has been in development for 15 years and has been subject to multiple reviews by European Food Safety Authority, UK Food Safety Authority AND others.

It has been extensively tested over months of exposure to cattle and has produced no unintended effects. Some studies actually say so improves the standard of milk and meat.

Bovaer was approved for use in dairy cattle by the European Union from 2022 and Japan in 2024. It is also utilized in many other countries, including: in beef products, amongst others Australia.

A really small amount of 3-NOP enters the environment (lower than 0.2% of the dose taken), no accumulates and is easily decomposed subsequently, it doesn’t pose a threat to the environment.

Since humans will not be exposed to 3-NOP through milk and meat, long-term exposure is not an issue.

What does Bill Gates have to do with this?

Bill Gates has invested in a distinct feed processing method for methane, Australian seaweed-based Rumin8. But he has nothing to do with Bovaer 10.

The Bill & Melinda Gates Foundation awarded research grants to the corporate producing 3-NOP for malaria control researchnot for 3-NOP.

The bottom line is that adding 3-NOP to animal feed doesn’t pose any risk to consumers, animals or the environment.

This article was originally published on : theconversation.com
Continue Reading
Advertisement

OUR NEWSLETTER

Subscribe Us To Receive Our Latest News Directly In Your Inbox!

We don’t spam! Read our privacy policy for more info.

Trending